Aug 7 (Reuters) - XBiotech Inc XBIT.O :
* Announces expansion of global phase 3 registration study in Europe using
Xilonix(TM) for treatment of metastatic colorectal cancer
* Xcite trial will continue to expand to include nearly 200 clinical sites
across 20 countries including Australia, Canada, South America
* Source text for Eikon ID:
* Further company coverage XBIT.O